Recently, researchers reported on 7-year interim results from the STRIVE registry and said that the results show that most children are able to tolerate adalimumab plus methotrexate well.
Children who have polyarticular juvenile idiopathic arthritis (JIA)—characterized by involvement of more than 4 joints within the first 6 months—tend to have more refractory disease and are at an increased risk for joint damage versus patients with other forms of JIA.
The emergence of biologics has improved the treatment of polyarticular JIA, though data are still accruing on the safety of these treatments in the pediatric population.
The STRIVE registry is assessing the long-term safety of adalimumab, with or without methotrexate, in patients with moderate to severe disease versus treatment with methotrexate alone. Patients enrolled in STIRVE will be followed for 10 years from enrollment into either the adalimumab or methotrexate arm. Recently, researchers reported on 7-year interim results from the registry, and said that the results show that most children are able to tolerate adalimumab plus methotrexate well.
Data from 838 patients were available at the cutoff date, with 301 patients in the methotrexate arm, and 537 patients in the methotrexate plus adalimumab arm. The most common adverse events (AEs) reported were nausea (10.3%), sinusitis (4.7%), and vomiting (4.3%) in the methotrexate-only arm, versus arthritis (3.9%), upper respiratory tract infection (3.5%), sinusitis (3.0%), tonsillitis (3.0%), and injection site pain (3.0%) in the adalimumab plus methotrexate arm.
Rates of serious infection were 1.5 events per 100 patient years in the methotrexate arm and 2.0 events per 100 patient years in the adalimumab plus methotrexate arm. Rates of AEs and serious AEs were similar between the 2 arms. No malignancies were reported, and no patients died.
According to the authors, these results demonstrate that most children can tolerate therapy with adalimumab and methotrexate up to 7 years, and no new safety signals were observed.
Reference
Brunner HI, Nanda K, Toth M, et al. Safety and effectiveness of adalimumab in patients with polyarticular course of juvenile idiopathic arthritis: STRIVE registry 7-year interim results [published online August 17, 2019]. Arthritis Care Res. doi: 10.1002/acr.24044.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.